Financial Market Analysis & Investment Research Partly open
Alnylam (ALNY): The "head and shoulders" pattern has played out—the target is approaching the gap
A continuation of the medium-term scenario for Alnylam (ALNY), dated July 31, 2026. The company is the pioneer and global leader in RNA interference, a technology that switches off the production of disease-causing proteins. The author reviews the second-quarter report and the cut to annual revenue guidance for the key TTR franchise, the outcome of the previous scenario and the chart's technical structure, with parameters for up to 12 months.
Already subscribed to «Financial Market Analysis & Investment Research»? Then sign in to read it. Sign in
Full version
The closed part follows
The full material is available with the «Financial Market Analysis & Investment Research 42$» subscription, or as a single view for $10.
- the full set of indicators and market factors;
- an interpretation of the current picture;
- conclusions and the signals that follow.
Sign in or register — then you can buy this material separately.